# Debate Matchup Judgment Report

**DeepSeek V4 Pro Preview** vs **GLM-5.2 (max)**

- Paired result: **DeepSeek V4 Pro Preview**
- Mean entertainment: `6.83 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Over the next five years, allowing Medicare to cover GLP-1–class anti-obesity drugs broadly will reduce total US healthcare spending after accounting for drug costs.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0582__deepseek-v4-pro__glm-5-2__s0__tpl_placement_active_20260320f.md): PRO = **DeepSeek V4 Pro Preview**, CON = **GLM-5.2 (max)**
- [Debate B transcript](../../../transcripts/prop_0582__glm-5-2__deepseek-v4-pro__s1__tpl_placement_active_20260320f.md): PRO = **GLM-5.2 (max)**, CON = **DeepSeek V4 Pro Preview**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0582__deepseek-v4-pro__glm-5-2__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **DeepSeek V4 Pro Preview**, CON = **GLM-5.2 (max)**
- Judged result: Split `2-1` for **DeepSeek V4 Pro Preview**.
- Entertainment scores: `7`, `5`, `8`
- Mean signed raw margin (PRO+): `+0.33`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | A = DeepSeek V4 Pro Preview (PRO); B = GLM-5.2 (max) (CON) | GLM-5.2 (max) | -2.0 | -2.14 | 7.0 |
| Grok 4.3 | A = DeepSeek V4 Pro Preview (PRO); B = GLM-5.2 (max) (CON) | DeepSeek V4 Pro Preview | +1.5 | +1.80 | 5.0 |
| Qwen 3.6 Max Preview | A = DeepSeek V4 Pro Preview (PRO); B = GLM-5.2 (max) (CON) | DeepSeek V4 Pro Preview | +1.5 | +1.50 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)** (A = DeepSeek V4 Pro Preview (PRO); B = GLM-5.2 (max) (CON)): B won by making the decisive arithmetic clearer: broad coverage creates continuous drug costs for millions, while A relied on cherry-picked avoided catastrophes without proving that the average persister generates enough expected savings to offset persisters and discontinuers combined. A landed a useful point that deferrals within five years count as savings, but B conceded and absorbed it, then refocused on probability and scale. A also suffered from clipped speeches and a late unsupported closing statistic.
  Most decisive rebuttal noted: B's strongest exchange was in Rebuttal 2 and closing: it reframed A's one avoided hospitalization examples as non-average, episodic savings, contrasting them with relentless monthly drug costs across all enrollees. That directly undercut A's central break-even story.
- **Grok 4.3** (A = DeepSeek V4 Pro Preview (PRO); B = GLM-5.2 (max) (CON)): Side A wins because it directly neutralized B's core routes (low persistence, additive costs, non-permanent savings) with plausible per-persister event-avoidance math and five-year window weighing that B only partially answered; B's closing shrinks savings to "modest" without rebutting the high per-event offsets A foregrounded.
  Most decisive rebuttal noted: A's Rebuttal 1 and 2 answers to B's adherence/window pressure, showing sunk dropout costs plus large event savings still net negative.
- **Qwen 3.6 Max Preview** (A = DeepSeek V4 Pro Preview (PRO); B = GLM-5.2 (max) (CON)): Side A wins by tightly leveraging the motion's explicit five-year constraint. When pressed on whether deferring a cost past year five counts as a saving inside the window, Side B conceded the point, effectively surrendering a major structural argument. Side A then successfully established that the high per-event cost of Medicare hospitalizations and surgeries creates a very low break-even persistence threshold, meaning even modest real-world adherence and partial event avoidance can mathematically offset continuous drug spend and early dropouts. Side B's counter that the average persister only sees modest lab improvements was well-articulated, but Side A's economic framing and cleaner alignment with the proposition's timeframe provided the more decisive path to victory.
  Most decisive rebuttal noted: Side A's Rebuttal 2 directly neutralized the adherence pressure by reframing the math: because a single avoided catastrophic event covers years of drug costs for multiple patients, the program does not need high persistence to break even. This turned Side B's strongest attack into a manageable variable and secured the core economic comparison.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0582__glm-5-2__deepseek-v4-pro__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **GLM-5.2 (max)**, CON = **DeepSeek V4 Pro Preview**
- Judged result: Unanimous `3-0` for **DeepSeek V4 Pro Preview**.
- Entertainment scores: `7`, `6`, `8`
- Mean signed raw margin (PRO+): `-1.60`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| GPT-5.5 (high) | A = GLM-5.2 (max) (PRO); B = DeepSeek V4 Pro Preview (CON) | DeepSeek V4 Pro Preview | -2.0 | -2.14 | 7.0 |
| Grok 4.3 | A = GLM-5.2 (max) (PRO); B = DeepSeek V4 Pro Preview (CON) | DeepSeek V4 Pro Preview | -1.3 | -1.56 | 6.0 |
| Qwen 3.6 Max Preview | A = GLM-5.2 (max) (PRO); B = DeepSeek V4 Pro Preview (CON) | DeepSeek V4 Pro Preview | -1.5 | -1.50 | 8.0 |

### Judge Notes

- **GPT-5.5 (high)** (A = GLM-5.2 (max) (PRO); B = DeepSeek V4 Pro Preview (CON)): Side B won by making the spending arithmetic clearer: immediate multi-year drug costs for millions of users swamp relatively slow and low-probability five-year medical offsets. Side A had plausible mechanisms and a good stacking argument, but relied heavily on speculative price collapse and drifted toward targeted risk stratification despite the motion's broad coverage framing. Side B's own specificity was sometimes approximate and several speeches were clipped, but its comparative weighing on price, timing, event rates, and broad low-risk uptake was more decisive.
  Most decisive rebuttal noted: Side B's strongest exchange was answering the “parallel lotteries” argument: even stacked diabetes, cardiac, and orthopedic offsets have low event rates and do not approach cumulative pharmacy costs unless prices fall to roughly $2,000 per year, which Side B argued was unrealistic within five years.
- **Grok 4.3** (A = GLM-5.2 (max) (PRO); B = DeepSeek V4 Pro Preview (CON)): B wins: stronger grounding on biologics pricing realities, broad-coverage mismatch, and realistic offset timing/magnitude after full exchange; multiple clips hurt B but did not erase substantive edge.
  Most decisive rebuttal noted: B's $2000 break-even concession plus A2 response on low-risk pool, which A never fully neutralized under the motion's broad requirement.
- **Qwen 3.6 Max Preview** (A = GLM-5.2 (max) (PRO); B = DeepSeek V4 Pro Preview (CON)): CON wins by effectively dismantling PRO's offset-stacking and price-drop assumptions. CON's distinction between small-molecule generic erosion and peptide/biologic pricing structures directly refuted PRO's core economic mechanism. CON also successfully leveraged the "broad coverage" wording to show PRO was quietly pivoting to risk-stratification, and provided a clear, falsifiable break-even threshold ($2k) that anchored the final clash. PRO's arguments were rhetorically polished but relied on optimistic timelines and a flawed drug-class comparison that CON exploited decisively.
  Most decisive rebuttal noted: CON's explanation that peptide manufacturing barriers and sterile fill-finish requirements prevent the 50-80% price crashes seen with statins, directly neutralizing PRO's primary path to a favorable five-year arithmetic.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0582`
- Side-swap group ID: `prop_0582__deepseek-v4-pro__glm-5-2__tpl_placement_active_20260320f`
- Raw paired winner: **DeepSeek V4 Pro Preview**
- Mean normalized margin for DeepSeek V4 Pro Preview: `+1.06`
- Complete side swap: `yes`
- Included in ratings: `yes`
